Alminoprofen, (+)- | 71589-39-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: Alminoprofen, (+)-
• 英文别名: (2S)-2-[4-(2-methylprop-2-enylamino)phenyl]propanoic acid
• CAS: 71589-39-4
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.28
• InChiKey: FPHLBGOJWPEVME-JTQLQIEISA-N

物化性质

• 沸点：
  373.1±30.0 °C(Predicted)
• 密度：
  1.107±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Combination
  申请人：——

  公开号：US20040242597A1

  公开（公告）日：2004-12-02

  The invention relates to the combined administration of PDE4-inhibitors and NSAIDs for the treatment of an inflammatory disease and/or an inflammation associated disorder while minimizing gastrointesti-nal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of NSAIDs.

  本发明涉及联合应用 PDE4 抑制剂和非甾体抗炎药治疗炎症性疾病和/或炎症相关疾病，同时最大限度地减少胃肠道副作用，如胃酸糜烂和溃疡，这些副作用经常与使用非甾体抗炎药有关。
• Combinations and use of selected pharmaceutically active compounds
  申请人：Buhr Wilm

  公开号：US20060154954A1

  公开（公告）日：2006-07-13

  The present invention relates to new combinations and new uses of certain selected tricyclic imidazo [ 1,2 -a]pyridine compounds in the prevention or treatment of medicament caused gastrointestinal diseases.

  本发明涉及某些精选三环咪唑[1,2]的新组合和新用途。 1,2 -a]吡啶化合物在预防或治疗药物引起的胃肠道疾病方面的新组合和新用途。
• COMBINATION OF A NSAID AND A PDE-4 INHIBITOR
  申请人：ALTANA Pharma AG

  公开号：EP1429807A2

  公开（公告）日：2004-06-23
• IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS
  申请人：ALTANA Pharma AG

  公开号：EP1599175A2

  公开（公告）日：2005-11-30
• Combination of a NSAID and a PDE-4 inhibitor
  申请人：Klein Thomas

  公开号：US20080255209A1

  公开（公告）日：2008-10-16

  The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE 4 inhibitor for this combination is roflumilast or a derivative thereof. A preferred conventional NSAID for this combination is diclofenac or a derivative thereof.